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A topic dermatitis (AD) is a chronic pruritic inflammatory skin disorder that is thought to be 
a multifactorial disease caused by both genetic and 
environmental factors [1].  AD is characterized by aller-
gic inflammation and epidermal barrier dysfunction 
[1].  Since a loss-of-function mutation of the filaggrin 
(FLG) gene has been reported to be a major predispos-
ing factor for AD [2],  primary epidermal barrier dys-
function is thought to be an initial event of the patho-
genesis of AD.  However,  there are quite a few AD 
patients who do not carry any FLG mutations,  and some 
individuals with a FLG loss-of-function mutation do not 
develop AD [3].  Therefore,  other genetic factors are 
also likely to be associated with the pathogenesis of AD.
Excessive protease activity is a characteristic abnor-
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Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is a large multidomain serine protease inhibitor that is 
expressed in epidermal keratinocytes.  Nonsense mutations of the SPINK5 gene,  which codes for LEKTI,  cause 
Netherton syndrome,  which is characterized by hair abnormality,  ichthyosis,  and atopy.  A single nucleotide 
polymorphism (SNP) of SPINK5,  p.K420E,  is reported to be associated with the pathogenesis of atopic derma-
titis (AD).  We studied all 34 exons of the SPINK5 gene in Japanese 57 AD patients and 50 normal healthy con-
trols.  We detected nine nonsynonymous variants,  including p.K420E; these variants had already been regis-
tered in the SNP database.  Among them,  p.R654H (n = 1) was found as a heterozygous mutation in the AD 
patients,  but not in the control.  No new mutation was detected.  We next compared the data of the AD patients 
with data from the Human Genetic Variation Database provided by Kyoto University; a significant difference 
was found in the frequency of the p.S368N genotype distribution.  PolyPhen-2 and SIFT,  two algorithms for 
predicting the functional effects of amino acid substitutions,  showed significant scores for p.R654H.  Therefore,  
R654H might be a risk factor for epidermal barrier dysfunction in some Japanese AD patients.
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mality that affects the epidermal barrier in AD patients 
[1 , 4].  In humans,  the kallikrein-related peptidases 
(KLKs) are 15 trypsin-like or chymotrypsin-like secreted 
serine proteases,  and in the skin,  mainly KLK5 and 
KLK7 are involved in the degradation of corneodesmo-
some proteins,  such as desmoglein 1,  desmocollin 1,  
and corneodesmosin,  leading to the desquamation of 
the corneal layers [5 , 6].  The expression and activity of 
several KLKs are increased in AD lesions,  and they 
trigger or enhance epidermal barrier dysfunction [4 , 7].  
In particular,  KLK7 has been shown to be induced 
by Th2 cytokines,  interleukin (IL)-4,  and IL-13 in epi-
dermal keratinocytes,  which might explain how the Th2 
environment exacerbates epidermal barrier dysfunction 
[8].  In addition,  KLK5 activates protease-activated 
receptor-2,  and it induces inflammatory cytokines and 
chemokines related to the Th2 environment in cells [9].
The KLK inhibitor lympho-epithelial Kazal-type-
related inhibitor (LEKTI) is a large multidomain serine 
protease inhibitor that is expressed in epidermal kerati-
nocytes,  and it tightly regulates KLK activities [6].  The 
SPINK5 gene encodes LEKTI.  Notably,  nonsense 
mutations of the SPINK5 gene cause Netherton syn-
drome,  which is characterized by hair abnormalities,  
ichthyosis,  and atopy [10 , 11].  A single nucleotide 
polymorphism (SNP) in SPINK5,  p.K420E (rs2303067),  
has been reported to be associated with AD [12-18].  
Fortugno et al.  showed that this variant has altered ser-
ine protease inhibitor function that results in protease 
deregulation,  which might be involved in the patho-
genesis of AD [19].  However,  several other groups have 
reported that there is no association between this vari-
ant and AD [20-24].
The effects of nonsynonymous SNPs or mutations in 
SPINK5 on the epidermal barrier seem to be very seri-
ous,  which suggests that other variants of the gene 
might also be involved in the pathogenesis of AD.  
Walley et al.  analyzed 33 exons of the SPINK5 gene in 
AD patients [16].  Many other groups have also focused 
on the analysis of exons 13,  14,  and 26 [12-15 , 17 ,  
18 , 20-24].  However,  it has been reported that there are 
34 exons in the SPINK5 gene and three splicing isoforms 
in humans [25].  Fig. 1 shows the genomic structure of 
the human SPINK5 gene and the splicing pattern of the 
isoforms (Fig. 1).  As far as we know,  no comprehensive 
analysis of all 34 exons of the SPINK5 gene has been 
reported in AD patients.  Here we studied all of the 
exons of the SPINK5 gene in Japanese AD patients.
Materials and Methods
Patient and control groups. This study was 
approved by the Ethics Committee of Okayama 
University (No.1605-027),  and was performed in 
accordance with the Helsinki Declaration.  The diagno-
sis of AD was based on the diagnostic criteria of Hanifin 
and Rajka,  and was made by dermatologists.  Blood 
samples for genetic analyses were collected with written 
informed consent from AD patients (n = 57; ages 
37.1 ± 10.6 years) and normal healthy controls 
(n = 50; ages 35.5 ± 11.1 years) at Okayama University 
Hospital and its affiliated hospitals or clinics.  We also 
compared the data of our AD patients with data from 
the Human Genetic Variation Database provided by 
Kyoto University (n = 1,029-1,205) < http://www.hgvd.
genome.med.kyoto-u.ac.jp/ > (accessed: August 2017).
Analysis of the SPINK5 gene. Genomic DNA was 
extracted from whole blood using the Wizard Genomic 
DNA Purification Kit (Promega,  Madison,  WI,  USA).  
All 34 exons were amplified with specific primers 
(Table 1),  and the polymerase change reaction (PCR) 
products were purified with exonuclease I and shrimp 
alkaline phosphatase (USB Corporation,  Cleveland,  
OH,  USA),  reacted with Big Dye Terminator (Applied 
Biosystems,  Foster City,  CA,  USA),  and analyzed with 
an ABI3100 DNA sequencer (Applied Biosystems) at the 
Central Research Laboratory,  Okayama University 
Medical School.
Polyphen-2. An algorithm for predicting the 
functional effects of amino acid substitutions,  
PolyPhen-2 < http://genetics.bwh.harvard.edu/pph2/ >,  
accessed August,  2017 was used.  Variants were pre-
dicted as ‘benign (score 0.0-0.15)’, ‘possibly damaging 
(0.15-1.0)’,  or ‘probably damaging (0.85-1.0)’.
SIFT. We used the algorithm SIFT < http://sift.
jcvi.org/ > to predict whether an amino acid substitu-
tion affects protein function.  SIFT scores range from 0 
to 1.  The amino acid substitution is predicted to be 
damaging if the score is ≤ 0.05,  and tolerated if the score 
is > 0.05.
Statistical analyses. Staistical analyses were per-
formed using IBM SPSS Statistics 20 (IBM,  Armonk,  
NY,  USA).  Odds ratios (ORs) were calculated with 
95% confidence intervals (CIs).  The correlation 
between genotypes and AD was examined by the Chi-
squared test.  Values of p < 0.05 were considered to be 
significant.
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Isoform A      1  MKIATVSVLLPLALCLIQDAASKNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDGIMFI
Isoform B      1  MKIATVSVLLPLALCLIQDAASKNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDGIMFI
Isoform C      1  MKIATVSVLLPLALCLIQDAASKNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDGIMFI
61  NKCATCKMILEKEAKSQKRARHLARAPKATAPTELNCDDFKKGERDGDFICPDYYEAVCG
61  NKCATCKMILEKEAKSQKRARHLARAPKATAPTELNCDDFKKGERDGDFICPDYYEAVCG
61  NKCATCKMILEKEAKSQKRARHLARAPKATAPTELNCDDFKKGERDGDFICPDYYEAVCG 
Isoform A  121  TDGKTYDNRCALCAENAKTGSQIGVKSEGECKSSNPEQDVCSAFRPFVRDGRLGCTREND
Isoform B  121  TDGKTYDNRCALCAENAKTGSQIGVKSEGECKSSNPEQDVCSAFRPFVRDGRLGCTREND
Isoform C  121  TDGKTYDNRCALCAENAKTGSQIGVKSEGECKSSNPEQDVCSAFRPFVRDGRLGCTREND
181  PVLGPDGKTHGNKCAMCAELFLKEAENAKREGETRIRRNAEKDFCKEYEKQVRNGRLFCT
181  PVLGPDGKTHGNKCAMCAELFLKEAENAKREGETRIRRNAEKDFCKEYEKQVRNGRLFCT
181  PVLGPDGKTHGNKCAMCAELFLKEAENAKREGETRIRRNAEKDFCKEYEKQVRNGRLFCT
Isoform A  241  RESDPVRGPDGRMHGNKCALCAEIFKQRFSEENSKTDQNLGKAEEKTKVKREIVKLCSQY
Isoform B  241  RESDPVRGPDGRMHGNKCALCAEIFKQRFSEENSKTDQNLGKAEEKTKVKREIVKLCSQY
Isoform C  241  RESDPVRGPDGRMHGNKCALCAEIFKQRFSEENSKTDQNLGKAEEKTKVKREIVKLCSQY
301  QNQAKNGILFCTRENDPIRGPDGKMHGNLCSMCQAYFQAENEEKKKAEARARNKRESGKA
301  QNQAKNGILFCTRENDPIRGPDGKMHGNLCSMCQAYFQAENEEKKKAEARARNKRESGKA
301  QNQAKNGILFCTRENDPIRGPDGKMHGNLCSMCQAYFQAENEEKKKAEARARNKRESGKA
Isoform A  361  TSYAELCSEYRKLVRNGKLACTRENDPIQGPDGKVHGNTCSMCEVFFQAEEEEKKKKEGK
Isoform B  361  TSYAELCSEYRKLVRNGKLACTRENDPIQGPDGKVHGNTCSMCEVFFQAEEEEKKKKEGK
Isoform C  361  TSYAELCSEYRKLVRNGKLACTRENDPIQGPDGKVHGNTCSMCEVFFQAEEEEKKKKEGK
421  SRNKRQSKSTASFEELCSEYRKSRKNGRLFCTRENDPIQGPDGKMHGNTCSMCEAFFQQE
421  SRNKRQSKSTASFEELCSEYRKSRKNGRLFCTRENDPIQGPDGKMHGNTCSMCEAFFQQE
421  SRNKRQSKSTASFEELCSEYRKSRKNGRLFCTRENDPIQGPDGKMHGNTCSMCEAFFQQE
Isoform A  481  ERARAKAKREAAKEICSEFRDQVRNGTLICTREHNPVRGPDGKMHGNKCAMCASVFKLEE
Isoform B  481  ERARAKAKREAAKEICSEFRDQVRNGTLICTREHNPVRGPDGKMHGNKCAMCASVFKLEE
Isoform C  481  ERARAKAKREAAKEICSEFRDQVRNGTLICTREHNPVRGPDGKMHGNKCAMCASVFKLEE
541  EEKKNDKEEKGKVEAEKVKREAVQELCSEYRHYVRNGRLPCTRENDPIEGLDGKIHGNTC
541  EEKKNDKEEKGKVEAEKVKREAVQELCSEYRHYVRNGRLPCTRENDPIEGLDGKIHGNTC
541  EEKKNDKEEKGKVEAEKVKREAVQELCSEYRHYVRNGRLPCTRENDPIEGLDGKIHGNTC
Isoform A  601  SMCEAFFQQEAKEKERAEPRAKVKREAEKETCDEFRRLLQNGKLFCTRENDPVRGPDGKT
Isoform B  601  SMCEAFFQQEAKEKERAEPRAKVKREAEKETCDEFRRLLQNGKLFCTRENDPVRGPDGKT
Isoform C  601  SMCEAFFQQEAKEKERAEPRAKVKREAEKETCDEFRRLLQNGKLFCTRENDPVRGPDGKT
661  HGNKCAMCKAVFQKENEERKRKEEEDQRNAAGHGSSGGGGGNTQDECAEYREQMKNGRLS
661  HGNKCAMCKAVFQKENEERKRKEEEDQRNAAGHGSSGGGGGNTQDECAEYREQMKNGRLS
661  HGNKCAMCKAVFQKENEERKRKEEEDQRNAAGHGSSGGGGGNTQDECAEYREQMKNGRLS
Isoform A  721  CTRESDPVRDADGKSYNNQCTMCKAKLEREAERKNEYSRSRSNGTGSESGKDTCDEFRSQ
Isoform B  721  CTRESDPVRDADGKSYNNQCTMCKAKLEREAERKNEYSRSRSNGTGSESGKDTCDEFRSQ
Isoform C  721  CTRESDPVRDADGKSYNNQCTMCKAKLEREAERKNEYSRSRSNGTGSESGKDTCDEFRSQ
781  MKNGKLICTRESDPVRGPDGKTHGNKCTMCKEKLEREAAEKKKKEDEDRSNTGERSNTGE
781  MKNGKLICTRESDPVRGPDGKTHGNKCTMCKEKLEREAAEKKKKEDEDRSNTGERSNTGE
781  MKNGKLICTRESDPVRGPDGKTHGNKCTMCKEKLEREAAEKKKKEDEDRSNTGERSNTGE
Isoform A  841  RSNDKEDLCREFRSMQRNGKLICTRENNPVRGPYGKMHINKCAMCQSIFDREANERKKKD
Isoform B  841  RSNDKEDLCREFRSMQRNGKLICTRENNPVRGPYGKMHINKCAMCQSIFDREANERKKKD
Isoform C  841  RSNDKEDLCREFRSMQRNGKLICTRENNPVRGPYGKMHINKCAMCQSIFDREANERKKKD
901  EEKSSSKPSNNAKDQCRQVQNEAEDAKFRQPGRSLASVARMSTDECSEFRNYIRNNELIC
901  EEKSSSKPSNNAK-------------------------------------------------------------------DECSEFRNYIRNNELIC
901  EEKSSSKPSNNAKVIY-------------------------------------------------------------------------------------------------
Isoform A  961  PRENDPVHGADGKFYTNKCYMCRAVFLTEALERAKLQEKPSHVRASQEEDSPDSFSSLDS
Isoform B  931  PRENDPVHGADGKFYTNKCYMCRAVFLTEALERAKLQEKPSHVRASQEEDSPDSFSSLDS
Isoform C  917  ------------------------------------------------------------------------------------------------------------------------------------
1021  EMCKDYRVLPRIGYLCPKDLKPVCGDDGQTYNNPCMLCHENLIRQTNTHIRSTGKCEESS
991  EMCKDYRVLPRIGYLCPKDLKPVCGDDGQTYNNPCMLCHENLIRQTNTHIRSTGKCEESS
917   ---------------------------------------------------------------------------------------------------------------------------------
Isoform A 1081  TPGTTAASMPPSDE
Isoform B 1051  TPGTTAASMPPSDE
Isoform C  917  -------------------------------
b
a
c
75kbCh5q320
Isoform A: 1,094aa
Isoform B: 1,064aa
Isoform C: 916aa
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Fig. 1　 SPINK5 gene structure.  a,  Genomic structure of the SPINK5 gene including 34 exons; b,  Amino acid alignment of splicing 
isoforms A-C; c,  Shames of exons 27-30 splicing pattern of isoforms A-C.  
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Table 1　 Primer for exons 1-34 of SPINK5
Exon No. Primer name Primer（Forward 5分 - 　-3分 ）
Coding exon 
length (bp)
Products 
length (bp)
1 SPINK5-E1-FW CCCATGACCTTGAACAACTGG 55 240
SPINK5-E1-RV TGAGATGTGTGGCAAGAGGCT
2 SPINK5-E2-FW CTGGTCCAGTGCCCTTCTTTT 26 277
SPINK5-E2-RV AGGTGTTGGCCACAAACCACT
3 SPINK5-E3-FW AGGCATTCTTTGAGGGCTTTAC 128 430
SPINK5-E3-RV AATGTCAGAGTGATCTGCTCAG
4 SPINK5-E4-FW TTTGACATGCCAGGCTAGGCT 73 311
SPINK5-E4-RV CCCTCCTAAGTTGTTGGCTTC
5 SPINK5-E5-FW ATTAGCTCAATGTAGCCTTCATGA 128 392
SPINK5-E5-RV ATTTAGGAATGGCTAACTCCCAC
6 SPINK5-E6-FW TCGGGAGTAAAGGAGAATGACAA 64 264
SPINK5-E6-RV TTCCAAGGCTCCCACCTAAGAA
7 SPINK5-E7-FW CACAGCTGGTACTGCTCTAAGT 128 393
SPINK5-E7-RV GTGAGAAAGGCTATTTCACAGTG
8 SPINK5-E8-FW TTGAAGACGGAAATGCTTGTCTC 64 281
SPINK5-E8-RV CTCAAAGGTTTAGGCATACATTTG
9 SPINK5-E9-FW TCTCTGAGCCTAGAGGTTAGAG 128 400
SPINK5-E9-RV GGGCATAAAACTGCTCAGATGG
10 SPINK5-E10-FW GGTCTTTTTGGGGATTTGAGGTG 88 276
SPINK5-E10-RV CACACACACACAAGTTGTAACT
11 SPINK5-E11-FW CATAGAAAACAGAACTATATCTCAAC 128 327
SPINK5-E11-RV CTCCCAGCTCTATCACTGATATT
12 SPINK5-E12-FW TAGCACCATACTATCCTGGAGG 82 336
SPINK5-E12-RV GGGCAAAATCTCACCCTTTAGG
13 SPINK5-E13-FW TTCCTATCTCTTGGCATATGATGT 128 453
SPINK5-E13-RV TGTCTCCAATCAGACAGTTTCTC
14 SPINK5-E14-FW CAGGGTTAGGCACATCACATTC 82 294
SPINK5-E14-RV TAAGGAATGCACGTGTTCCCTG
15 SPINK5-E15-FW TTTCTTGGTTGTTGGGTTCATTGT 128 434
SPINK5-E15-RV TATGACACCCAAGACTGAATGCT
16 SPINK5-E16-FW GCTATGAAAGTTAAGGATCTAGTC 49 596
SPINK5-E16-RV GGACACTTCTTATCAGGACCC
17 SPINK5-E17-FW CAATTCTGATTGATGACGGAAGC 128 391
SPINK5-E17-RV AACTCACGGTCTATACTCTACAC
18 SPINK5-E18-FW GCAAAAGCACCTCTCAGACTAG 85 441
SPINK5-E18-RV ATTGATCTCTCTCCTGCACGAG
19 SPINK5-E19-FW CTTTCACAGTGCCTAGTGCAG 128 451
SPINK5-E19-RV CTTCCAATGTCACCCCTCTTG
20 SPINK5-E20-FW GATGTGTGTTTACCTTTCCACTC 67 336
SPINK5-E20-RV AACCCCTGGACTAAATGAACCC
21 SPINK5-E21-FW TACAGCCACCTTCTTAAGTCCTT 128 482
SPINK5-E21-RV CTAGAACTGTGAATCTTGGCCAT
22 SPINK5-E22-FW TAGAGAAGGCCTGCAGCATAGT 97 417
SPINK5-E22-RV ACCCCAGAGCAGTGAAAATGTG
23 SPINK5-E23-FW ACCGTACCCGGCAATGTTATGT 128 432
SPINK5-E23-RV CCTTGCTAAGGCTCATTGTTCC
24 SPINK5-E24-FW CGGCCATTTGGAATCATTGACC 73 331
SPINK5-E24-RV GGTAACTCCTGACCTTCTAAGG
25 SPINK5-E25-FW TCACAGCAAGGTTACATGGCTG 128 467
SPINK5-E25-RV GCTCCTTTCTCCTGTATTGCTC
26 SPINK5-E26-FW CATCTGCACTCGAGAAAGTGAC 97 435
SPINK5-E26-RV TGGGACAGAGTCAGCATTTCAC
27 SPINK5-E27-FW CCTGTGTTATGAGTTTATATCTAATCGG 128 323
SPINK5-E27-RV ATGTGTGATGCCAAGTATCTTAGG
28 SPINK5-E28-FW GGTATAAGAAAACAGTGTTAGATTTGC 73 448
SPINK5-E28-RV CATATTTCTCCCAAGGAGGAAAGAC
29+30 SPINK5-E29-FW GTTAGATCCCTGAGCAATTGTCC 90+128 611
SPINK5-E30-RV CAGGTGTTCTCAATTTGAGGGC
31 SPINK5-E31-FW GGTTACAGGCGTGAACTACCAT 97 341
SPINK5-E31-RV ACTTCAGGCTGCACTGAATCAG
32 SPINK5-E32-FW TCCACCTCATATGGTGCAAAATC 131 365
SPINK5-E32-RV TATGGGTTAACACTCTAGCTGAG
33 SPINK5-E33-FW TGAATGCAGATCCCAGATCCTC 91 364
SPINK5-E33-RV TGACCAATTCTGGGTCACCTGA
34 SPINK5-E34-FW TGCTACTTCTTTGCAGAATGCAG 9 289
SPINK5-E34-RV TGAAAATCAGTGAGTCCATTCCC
The primers were designed to amplify and sequence 34 exons. Exons 29 and 30 were ampliﬁed together.
Results
Nine nonsynonymous variants,  including p.K420E,  
were detected (Table 2); these variants had already 
been registered in the SNP database (dbSNP).  We also 
found 10 synonymous variants (data not shown).  No 
new mutation was detected in this study.  We found no 
significant difference in the frequency of p.K420E 
between the AD patient group and control group.  
Similarly,  we found no significant difference in the fre-
quencies of p.D106N (rs17860502),  p.Q267R 
(rs6892205),  p.A335V (rs34482796),  p.S368N 
(rs2303063),  p.D386N (rs2303064),  p.R711Q 
(rs3777134),  or p.E825D (rs2303070) between the two 
groups.  However,  among the nine variants,  p.R654H 
(n = 1) was found as a heterozygous variant in the AD 
patient group,  but not in the control group.  Although 
p.R654H has been reported as rs182767534 in dbSNP 
< https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.
cgi?rs=182767534 > (accessed August 2017),  the fre-
quency of heterozygosity was < 0.001.
We next compared the data of our AD patients with 
data from the Human Genetic Variation Database pro-
vided by Kyoto University (Table 3),  because the num-
ber of controls in our cohort was small.  The frequency 
of p.R654H was 4 heterozygotes per 1,200 people in the 
Human Genetic Variation Database,  indicating that the 
frequency of p.R654H did not differ significantly.  Only 
the frequency of S368N differed significantly between 
our AD patients and the data of the Human Genetic 
Variation Database (p = 0.048).  The Polyphen-2 algo-
rithm for predicting the functional effects of amino acid 
substitutions showed that the scores of p.R654H and 
p.S368N were 1.000 (probably damaging) and 0.002 
(benign),  respectively.  The other algorithm,  SIFT,  
indicated a significant score (0.05,  i.e.,  damaging) for 
p.R654H.
Discussion
LEKTI consists of 15 domains (D1 to D15),  and 
each domain has a Kazal-type structure that is thought 
to function as a serine protease inhibitor [10].  The frag-
ments of LEKTI processing,  including D6D9,  D7D9,  
D8D9,  D10D15,  and D10D13,  are also bioactive [26].  
p.K420E has been shown to change the cleavage pattern 
of D6D9,  and to change the function of serine protease 
inhibitors [19],  indicating that the substitution of even 
a single amino acid is capable of significantly affecting 
the function of the LEKTI protein.  In our study,  there 
was no difference in the frequency of p.K420E between 
the AD patient group and the control group.  However,  
some other Japanese groups have reported an associa-
tion between this variant and AD [13-15],  suggesting 
that there might be regional differences even in Japan.
p.R654H is located within D10,  and both the 
PolyPhen-2 and SIFT algorithms showed significant 
scores for this variant.  Similar to p.K420E,  p.R654H 
might also affect the functions of LEKTI fragments,  
including D10,  D10D13,  and D10D15.
The frequency of the p.S368N genotype differed sig-
nificantly between our AD patients and the data from 
the Human Genetic Variation Database (p = 0.048).  As 
shown in Table 3,  the OR of the AA genotype (Asn) of 
p.S368N was 0.41 (i.e., < 1),  and the 95% CI was 0.17 to 
0.991 ( < 1),  suggesting that this genotype might be a 
protective SNP that protects against the occurrence of 
AD in Japanese subpopulations.  Although the fre-
quency of the genotype did not differ significantly 
between the AD patients and the control in the present 
study,  a large-scale cohort study would be necessary to 
confirm and clarify this result in future analyses.  
In conclusion,  we performed a sequencing analysis 
of all 34 exons of the SPINK5 gene; no such compre-
hensive analysis of all 34 exons had been reported,  to 
our knowledge.  Nine nonsynonymous variants were 
detected,  although no new mutation was found.  We 
detected p.R654H only in the AD patients,  not the con-
trol,  and p.R654H might be a risk factor for epidermal 
barrier dysfunction in some Japanese AD patients.  
Further investigations,  such as a large-scale cohort 
analysis and a functional analysis using mutant proteins,  
are required to clarify the clinical significance of the 
p.R654H variant in AD.  The frequency of this variant 
should also be evaluated in other ethnicities.
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Table 2　 Nonsynonymous variants of SPINK5 in Japanese AD patients
Amino acid Genotype AD (n=57) Control (n=50) P value OR 95% Conf.  Interval
D106N GG 36 30
GA 18 18 0.66  0.833 0.372 1.866
AA 3  2 0.813 1.25 0.232 6.667
GA+AA 21 20 0.737 0.875 0.403 1.899
(Allele frequencies) G 90 78
A 24 22 0.866 0.945 0.495 1.806
Q267R AA 22 19
GA 29 22 0.759 1.138 0.501 2.587
GG 6 9 0.365 0.576 0.179 1.861
GA+GG 35 31 0.95 0.975 0.449 2.118
(Allele frequencies) A 73 60
G 41 40 0.544 0.842 0.485 1.462
A335V CC 22 19
CT 29 22 0.759 1.138 0.501 2.587
TT 6 9 0.365 0.576 0.179 1.861
CT+TT 35 31 0.95 0.975 0.449 2.118
(Allele frequencies) C 73 60
T 41 40 0.544 0.842 0.485 1.462
S368N GG 24 19
GA 27 22 0.945 0.972 0.429 2.202
AA 6 9 0.291 0.528 0.165 1.695
GA+AA 33 31 0.666 0.847 0.39 1.822
(Allele frequencies) G 75 60
A 39 40 0.381 0.78 0.448 1.358
D386N GG 13 17
GA 26 21 0.305 1.619 0.649 4.037
AA 18 12 0.196 1.962 0.71 5.419
GA+AA 44 33 0.198 1.744 0.751 4.043
(Allele frequencies) G 52 55
A 62 45 0.171 1.457 0.851 2.495
K420E AA 22 19
GA 29 22 0.759 1.138 0.501 2.587
GG 6 9 0.365 0.576 0.179 1.861
GA+GG 35 31 0.95 0.975 0.449 2.118
(Allele frequencies) A 73 60
G 41 40 0.544 0.842 0.485 1.462
R654H GG 56 50
GA 1 0 0.347 Inf 0.227 Inf
AA 0 0 1 NaN NaN NaN
GA+AA 1 0 0.347 Inf 0.227 Inf
(Allele frequencies) G 113 100
A 1 0 0.348 Inf 0.228 Inf
R711Q GG 21 19
GA 28 21 0.661 1.206 0.524 2.776
AA 8 10 0.57 0.724 0.242 2.169
GA+AA 36 31 0.902 1.051 0.482 2.289
(Allele frequencies) G 70 59
A 44 41 0.72 0.905 0.524 1.563
E825D GG 28 33
GT 26 16 0.11 1.915 0.865 4.239
TT 3 1 0.259 3.536 0.47 25.819
GT+TT 29 17 0.079 2.011 0.924 4.371
(Allele frequencies) G 82 82
T 32 18 0.082 1.778 0.93 3.396
All 34 exons of SPINK5 were ampliﬁed with speciﬁc primers and sequenced with an ABI3100 DNA sequencer.  Nine nonsynonymous variants were found in this 
analysis.  OR,  odds ratio; Inf,  inﬁnity; NaN,  Not a Number.
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Table 3　 Nonsynonymous variants of SPINK5 in Japanese AD patients (The comparison with the Human Genetic Variation Database)
Amino acid Genotype AD (n=57) Kyoto Database P 
value
OR 95% Conf. Interval
D106N GG 36 719
GA 18 271 0.341 1.327 0.746  2.36
AA 3 39 0.487 1.536 0.483  4.914
GA+AA 21 310 0.284 1.353 0.782  2.342
(Allele frequencies) G 90 1709
A 24 349 0.259 1.306 0.824  2.071
Q267R AA 22 368
GA 29 562 0.612 0.863 0.491  1.516
GG 6 231 0.068 0.434 0.179  1.059
GA+GG 35 793 0.276 0.738 0.429  1.269
(Allele frequencies) A 73 1298
G 41 1024 0.087 0.712 0.483  1.05
A335V CC 22 371
CT 29 601 0.477 0.814 0.464  1.428
TT 6 233 0.067 0.434 0.179  1.058
CT+TT 35 834 0.214 0.708 0.412  1.216
(Allele frequencies) C 73 1343
T 41 1067 0.081 0.707 0.479  1.043
S368N GG 24 377
GA 27 547 0.377 0.775 0.443  1.356
AA 6 230 0.048 0.41 0.17  0.991
GA+AA 33 777 0.139 0.667 0.391  1.138
(Allele frequencies) G 75 1301
A 39 1007 0.047 0.672 0.453  0.996
D386N GG 13 331
GA 26 585 0.721 1.132 0.58  2.207
AA 18 254 0.11 1.804 0.88  3.7
GA+AA 44 839 0.368 1.335 0.716  2.488
(Allele frequencies) G 52 1247
A 62 1093 0.184 1.286 0.888  1.862
K420E AA 22 355
GA 29 460 0.953 1.017 0.578  1.789
GG 6 231 0.056 0.419 0.172  1.022
GA+GG 35 691 0.47 0.817 0.475  1.406
(Allele frequencies) A 73 1170
G 41 922 0.089 0.713 0.483  1.053
R654H GG 56 1200
GA 1 4 0.095 5.357 0.795 36.477
AA 0 0 1 NaN NaN NaN
GA+AA 1 4 0.095 5.357 0.795 36.477
(Allele frequencies) G 113 2404
A 1 4 0.095 5.319 0.795 35.79
R711Q GG 21 382
GA 28 581 0.656 0.877 0.494  1.555
AA 8 218 0.338 0.668 0.297  1.503
GA+AA 36 799 0.479 0.82 0.475  1.415
(Allele frequencies) G 70 1345
A 44 1017 0.347 0.831 0.566  1.22
E825D GG 28 670
GT 26 436 0.201 1.427 0.83  2.452
TT 3 85 0.784 0.845 0.268  2.673
GT+TT 29 521 0.289 1.332 0.787  2.255
(Allele frequencies) G 82 1776
T 32 606 0.53 1.144 0.754  1.734
Nine nonsynonymous variants found in this analysis were compared with the Human Genetic Variation Database.  OR,  odds ratio; NaN,  Not a Number.
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